Alkermes Stock Earnings Estimates Increased by HC Wainwright

Alkermes plc (NASDAQ:ALKS) – Research analysts at HC Wainwright increased their FY2026 EPS estimates for shares of Alkermes in a report issued on Wednesday, November 4th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.56) for the year, up from their prior estimate of ($0.71). HC Wainwright currently has a “Neutral” rating and a $50.00 target price on the stock. The consensus estimate for Alkermes’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Alkermes’ Q4 2026 earnings at ($0.28) EPS, Q1 2027 earnings at ($0.03) EPS, Q2 2027 earnings at $0.08 EPS, Q3 2027 earnings at $0.16 EPS, Q4 2027 earnings at $0.03 EPS, FY2027 earnings at $0.24 EPS, FY2028 earnings at $0.08 EPS, FY2029 earnings at $0.86 EPS and FY2030 earnings at $1.66 EPS.

A number of other analysts also recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $62.00 target price on shares of Alkermes in a research report on Monday, September 21st. Weiss Ratings restated a “hold (c)” rating on shares of Alkermes in a research report on Wednesday, November 4th. TD Cowen restated a “buy” rating on shares of Alkermes in a research report on Monday, September 21st. JPMorgan Chase & Co. lifted their price target on Alkermes from $60.00 to $61.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. Finally, The Goldman Sachs Group started coverage on shares of Alkermes in a research report on Thursday, September 24th. They issued a “neutral” rating and a $50.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $55.06.

Alkermes Stock Performance

Shares of ALKS stock opened at $46.47 on Wednesday. The stock has a fifty day moving average price of $43.67 and a 200 day moving average price of $40.92. The stock has a market cap of $7.81 billion, a PE ratio of -2,322.34 and a beta of 0.32. Alkermes has a 1 year low of $27.00 and a 1 year high of $55.67. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.02 and a current ratio of 2.42.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.17. The business had revenue of $480.13 million for the quarter, compared to analysts’ expectations of $463.48 million. Alkermes had a positive return on equity of 0.40% and a negative net margin of 0.02%. The company’s revenue was up 21.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.49 EPS.

Hedge Funds Weigh In On Alkermes

Several hedge funds have recently bought and sold shares of ALKS. Baird Financial Group Inc. purchased a new stake in shares of Alkermes in the second quarter valued at $2,791,000. S&CO Inc. purchased a new stake in Alkermes during the 2nd quarter worth about $12,824,000. Quantinno Capital Management LP increased its position in Alkermes by 131.1% during the 1st quarter. Quantinno Capital Management LP now owns 44,932 shares of the company’s stock worth $1,589,000 after purchasing an additional 25,492 shares in the last quarter. Hennion & Walsh Asset Management Inc. purchased a new stake in Alkermes during the 2nd quarter worth about $2,479,000. Finally, Seven Fleet Capital Management LP acquired a new position in Alkermes in the 1st quarter valued at about $855,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Insider Activity

In other news, SVP Christian Nichols sold 7,576 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $49.23, for a total transaction of $372,966.48. Following the completion of the transaction, the senior vice president directly owned 102,193 shares of the company’s stock, valued at $5,030,961.39. This trade represents a 6.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Gaffin sold 2,035 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $46.17, for a total transaction of $93,955.95. Following the transaction, the executive vice president directly owned 219,353 shares of the company’s stock, valued at approximately $10,127,528.01. This trade represents a 0.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 22,679 shares of company stock worth $1,070,940 over the last ninety days. 4.59% of the stock is currently owned by insiders.

More Alkermes News

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: HC Wainwright raised its FY2027–FY2030 EPS forecasts, including moving FY2027 to $0.24 from a projected loss of $0.43 and FY2030 to $1.66 from $1.36. The improved outlook for later-year earnings may support investor optimism. Article: What Are Investment Firms Saying About This Stock?
• Neutral Sentiment: The firm kept its Neutral rating and $50 price target. It forecasts a return to positive annual EPS in 2027, while estimating a loss of $0.56 per share for 2026.
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to a loss of $0.28 per share from a loss of $0.23, a near-term earnings revision that could weigh on sentiment.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.